Helixgate

Helixgate

Uncategorized

Webinar: Aligning With the FDA on a Regulatory Pathway To Avoid Decision Day Surprises

Published

on

Watch this critical discussion on how regulators and biotech companies can bridge the expectation gap during the regulatory review process to ensure novel therapies reach patients in a timely manner—because patients don’t have time to wait.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Terns rebuffed a higher bid before selling to Merck

Regulatory filings show that Terns ultimately accepted an offer 15% lower than a previous proposal as four companies vied for rights to the coveted leukemia drug developer. 

Read More

Published

on

Regulatory filings show that Terns ultimately accepted an offer 15% lower than a previous proposal as four companies vied for rights to the coveted leukemia drug developer. 

Read More

Continue Reading

Uncategorized

STAT+: States looking to regulate use of chatbots

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.

Good morning health tech readers!

Today, a deep dive into why America’s most powerful health insurer is looking more and more like a technology company. 

Continue to STAT+ to read the full story…

Read More

Published

on

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.

Good morning health tech readers!

Today, a deep dive into why America’s most powerful health insurer is looking more and more like a technology company. 

Continue to STAT+ to read the full story…

Read More

Continue Reading

Uncategorized

ARPA-H selects three teams in $100M effort to repair and regrow ailing joints

Published

on

Three academic centers believe they may have discovered new ways to heal aging joints. Now the federal government is funding clinical trials to test these experimental regenerative medicines in osteoarthritis.
Teams from Duke University, the …

Continue Reading
Advertisement

Trending